Payment overview · 2025
General Payments
$387.95
22 reported records · 10 companies
Healthcare provider profile · identity verified
James Emil Rocco, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WAKEFIELD, MI · NPI 1710075346
Verified facts
What the public records show
CMS Open Payments records show James Emil Rocco, M.D. received $387.95 in general payments during 2025 across 22 reported records.
Exact Sciences Corporation accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Otezla.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 583 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.31 | 18.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.62 | 17.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.82 | 13.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.65 | 11.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.36 | 10.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.50 | 8.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.53 | 5.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.52 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.83 | 4.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.81 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $387.95 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $73.31 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.62 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.62 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.65 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 583 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
583 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 1264 | 113 |
| Lisinopril | Lisinopril | 872 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 799 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 781 | 111 |
| Potassium Chloride | Potassium Chloride | 758 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 745 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 75 |
| Omeprazole | Omeprazole | 612 | 98 |
| Eliquis | Apixaban | 583 | 43 |
| Sertraline Hcl | Sertraline Hcl | 505 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 464 | 64 |
| Metformin Hcl | Metformin Hcl | 457 | 74 |
| Simvastatin | Simvastatin | 444 | 73 |
| Losartan Potassium | Losartan Potassium | 423 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 403 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 371 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 328 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 327 | 41 |
| Lorazepam | Lorazepam | 326 | 70 |
| Gabapentin | Gabapentin | 312 | 46 |
| Mirtazapine | Mirtazapine | 293 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 35 |
| Warfarin Sodium | Warfarin Sodium | 236 | 16 |
| Trazodone Hcl | Trazodone Hcl | 234 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 35 |
| Tramadol Hcl | Tramadol Hcl | 206 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 19 |
| Risperidone | Risperidone | 192 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 184 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 176 | 14 |
| Meloxicam | Meloxicam | 169 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 169 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 16 |
| Glipizide | Glipizide | 154 | 26 |
| Olanzapine | Olanzapine | 149 | 13 |
| Allopurinol | Allopurinol | 145 | 26 |
| Ezetimibe | Ezetimibe | 145 | 27 |
| Fentanyl | Fentanyl | 143 | 16 |
| Prednisone | Prednisone | 141 | 39 |
| Xarelto | Rivaroxaban | 140 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 132 | 11 |
| Montelukast Sodium | Montelukast Sodium | 131 | 16 |
| Baclofen | Baclofen | 130 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 21 |
| Carvedilol | Carvedilol | 119 | 21 |
| Levetiracetam | Levetiracetam | 119 | 13 |
| Alprazolam | Alprazolam | 118 | 19 |
| Enalapril Maleate | Enalapril Maleate | 117 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 14 |
| Famotidine | Famotidine | 114 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 18 |
| Azithromycin | Azithromycin | 102 | 82 |
| Aripiprazole | Aripiprazole | 100 | suppressed |
| Nystatin | Nystatin | 96 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 87 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 14 |
| Spironolactone | Spironolactone | 84 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 14 |
| Hydrocortisone | Hydrocortisone | 77 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 75 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 75 | 12 |
| Digoxin | Digoxin | 74 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 73 | suppressed |
| Jardiance | Empagliflozin | 73 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 72 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | suppressed |
| Scopolamine | Scopolamine | 70 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 40 |
| Lidocaine | Lidocaine | 66 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 65 | suppressed |
| Bumetanide | Bumetanide | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 64 | 13 |
| Lamotrigine | Lamotrigine | 63 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Lovastatin | Lovastatin | 61 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 61 | 29 |
| Albuterol Sulfate | Albuterol Sulfate | 60 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Cephalexin | Cephalexin | 59 | 38 |
| Finasteride | Finasteride | 59 | 12 |
| Terazosin Hcl | Terazosin Hcl | 59 | 13 |
| Ondansetron Odt | Ondansetron | 57 | 12 |
| Ibuprofen | Ibuprofen | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 37 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Latanoprost | Latanoprost | 51 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Sucralfate | Sucralfate | 46 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 34 | 18 |
| Probenecid | Probenecid | 34 | suppressed |
| Folic Acid | Folic Acid | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Nystop | Nystatin | 33 | 21 |
| Phenytoin | Phenytoin | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 30 |
| Anastrozole | Anastrozole | 31 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Clozapine | Clozapine | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 16 |
| Nadolol | Nadolol | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Lamotrigine Er | Lamotrigine | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 20 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Otezla | Apremilast | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $387.95 · 22 records | Exact Sciences Corporation | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, GVOKE HYPOPEN, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error